medigraphic.com
ISSN 0035-0052 (Print)

2022, Number 1

<< Back Next >>

Rev Mex Pediatr 2022; 89 (1)

Hepatitis B antibody levels in adolescents: comparison of children vaccinated at birth versus vaccinated at 12 months of age

Calva-Rodríguez R, Ruiz-Arenas R, Ávila-Ramírez C, Calva-Ariza P, Rivera-Domínguez ME, Coronel-Cruzado L, Sánchez-Rodríguez G

Language: Spanish
References: 26
Page: 36-39
PDF size: 207.46 Kb.


ABSTRACT

Objective: to compare the levels of protective antibodies against hepatitis B virus in 14-year-old patients, between those vaccinated at birth and those vaccinated at one year of age. Material and methods: cross-sectional study with 62 healthy patients. Hepatitis B surface antigen (anti-HBs) antibody levels were measured; values > 10 IU/mL were considered protective. Results: of the total, 40 patients (64.5%) were vaccinated at birth and 22 (35.5%) at one year of age. Serum levels in the latter group were statistically higher, with no difference by sex. Twenty-four patients (38.7%) achieved protective levels, eight (33.3%) from the group vaccinated at birth, and 16 (66.6%) from the other group. Conclusions: vaccination against hepatitis B at one year of age seems to generate a greater probability of obtaining protective antibody titers at the age of 14 years.


REFERENCES

  1. World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017.

  2. Organización Mundial de la Salud. Hepatitis B. 218. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hepatitis-b

  3. Karnik R, Singal AG. To "b" or not to "b": efficacy of a neonatal hepatitis b vaccination program to prevent primary liver cancer and end-stage liver disease. Gastroenterology. 2015; 148(5): 1073-1075.

  4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373(9663): 582-592.

  5. Román S, Panduro A, Aguilar-Gutiérrez Y, Maldonado M, Vazquez-van Dyck M, Martínez-López E et al. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int. 2009; 3(2): 343-355.

  6. Cisneros-Castolo M, Hernández-Ruiz L, Ibarra-Robles IE, Fernández-Gárate RH, Escobedo-De la Peña J. Prevalence of hepatitis B virus infection and related risk factors in a rural community of Mexico. Am J Trop Med Hyg. 2001; 65(6): 759-763.

  7. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009; 49(5 Suppl): S45-S55.

  8. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010; 14(1): 1-21, vii.

  9. Yonghao G, Pumei D, Jianhui Y, Jin X, Yanyang Z, Zhe W. A retrospective study of hepatitis B mother-to-child transmission prevention and postvaccination serological test results of infants at risk of perinatal transmission in two counties of middle China. J Viral Hepat. 2017; 24(8): 687-695.

  10. Architect System. (September de 2013). HBsAg Qualitative II - B2G220. ABBOTT DIAGNOSTICS.

  11. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol. 2009; 50(4): 805-816.

  12. Secretaría de Salud. Vacunación Universal. Programa Sectorial de Salud 2013-2018. México DF, México: Secretaría de Salud; 2014.

  13. Escobar GA, Valdespino JL, Sepúlveda J. Vacuna, ciencia y salud. México: Secretaría de Salud; 1992. pp. 205-215.

  14. Panduro A, Escobedo M, Fierro N, Ruiz M, Zepeda C, Roman S. Epidemiología de las hepatitis virales en México. Salud Púb Mex. 2011; 53(Suppl 1): S37-S45.

  15. Puliyel J, Naik P, Puliyel A, Agarwal K, Lal V, Kansal N et al. Evaluation of the protection provided by hepatitis B vaccination in India. Indian J Pediatr. 2018; 85(7): 510-516.

  16. Marion S, Tomm PM, Pi D, Mathias R. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994; 140(8): 734-746.

  17. Middleman A. Hepatitis B infant immunization protects through adolescent years. Pediatrics. 2014; 133(6): e1500-e1507.

  18. Agladioglu S, Beyazova U, Camurdan A, Sahin F, Atak A. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules. Infection. 2010; 34(4): 269-273.

  19. Chiara F, Bartolucci G, Mongillo M, Ferreto L, Nicolli A, Trevisan A. Hepatitis B vaccination at three months of age: a succesful strategy? Vaccine. 2013; 31(13): 1696-1700.

  20. Shete P, Daum R. Real versus theoretical: assesing the risks and benefits of postponing the hepatitis B vaccine birth dose. Pediatrics. 2002; 109(4): 701-703.

  21. Bartholomeus E, De NN, Meysman P, Suls A, Keersmaekers N, Elias G et al. Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non responders. Vaccine. 2018; 36(42): 6282-6289.

  22. García Llop L, Asensi AA, Coll MP, Ramada BA, Grafiá JC. Títulos de anti-HBs tras un programa de vacunación en niños y adolescentes: ¿revacunar? An Pediatr. 2001; 54(1): 32-37.

  23. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000; 355(9203): 561-565.

  24. Klinger G, Chodick G, Levy I. Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis. Vaccine. 2018; 36(17): 2288-2292.

  25. Jafarzadeh A, Khoshnoodi J, Ghorbani S, Hazrati SM, Mazaheri BF, Shokri F. Differential immunogenicity of a recombinant hepatitis B vaccine in iranian neonates: influence of ethnicity and environmental factors. Iran J Immunol. 2004; 1(2): 98-104.

  26. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. Morb Mortal Wkly Rep. 2005; 54: 1-31.




2020     |     www.medigraphic.com